Viracta Therapeutics (VIRX) Stock Chart & Stock Price History $0.16 0.00 (0.00%) (As of 05:45 PM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Viracta Therapeutics Stock Price Performance 5 Day Performance-36.00%1 Month Performance+14.29%3 Month Performance-30.86%6 Month Performance-70.57%Year-To-Date Performance-71.93%1 Year Performance-71.93% Receive VIRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TSLA *BANG* incoming (bullet in the chamber rn) (Ad)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. VIRX Stock Chart for Monday, December, 30, 2024 VIRX Chart by TradingView Viracta Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/27/2024$0.24$0.16-32.49%$0.21$0.159.37 million shs$6.36 million12/26/2024$0.25$0.24-5.20%$0.26$0.23797,758 shs$9.42 million12/25/2024$0.25$0.25$0.26$0.23366,684 shs$9.94 million12/24/2024$0.23$0.25+7.43%$0.26$0.23366,684 shs$9.94 million12/23/2024$0.21$0.23+10.81%$0.25$0.22627,239 shs$9.25 million12/20/2024$0.21$0.21-1.87%$0.26$0.211.70 million shs$8.35 million Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/19/2024$0.21$0.21+3.63%$0.22$0.20484,195 shs$8.51 million12/18/2024$0.22$0.21-4.22%$0.23$0.211.05 million shs$8.21 million12/17/2024$0.21$0.22+1.70%$0.22$0.19740,004 shs$8.57 million12/16/2024$0.20$0.21+4.59%$0.22$0.181.22 million shs$8.43 million12/13/2024$0.19$0.20+6.80%$0.21$0.18732,553 shs$8.06 million12/12/2024$0.18$0.19+8.03%$0.20$0.171.51 million shs$7.54 million12/11/2024$0.17$0.18+3.35%$0.18$0.16611,646 shs$6.98 million12/10/2024$0.17$0.17-2.41%$0.18$0.161.08 million shs$6.76 million12/09/2024$0.16$0.17+10.60%$0.19$0.142.49 million shs$6.92 million12/06/2024$0.16$0.16+0.96%$0.17$0.152.31 million shs$6.26 million12/05/2024$0.18$0.16-14.43%$0.17$0.153.54 million shs$6.20 million12/04/2024$0.16$0.18+11.98%$0.20$0.1643.63 million shs$7.25 million12/03/2024$0.16$0.16+2.07%$0.17$0.159.40 million shs$6.47 million12/02/2024$0.14$0.16+13.93%$0.16$0.142.99 million shs$6.34 million11/29/2024$0.15$0.14-3.31%$0.15$0.142.07 million shs$5.68 million Related Companies CVM Stock Price Chart ENLV Stock Price Chart CVKD Stock Price Chart LPCN Stock Price Chart LSTA Stock Price Chart PULM Stock Price Chart LVTX Stock Price Chart NKGN Stock Price Chart INKT Stock Price Chart PLUR Stock Price Chart Receive VIRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:VIRX) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
